Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
BriaCell Therapeutics is a clinical-stage biotechnology company developing targeted immunotherapies for advanced breast cancer, with lead candidate Bria-IMT™ (a whole-cell cancer vaccine combined with immune checkpoint inhibitors) in Phase I/II trials. The company has no revenue, operates with a cash burn model typical of early-stage oncology developers, and faces binary clinical trial outcomes as primary value drivers. Recent severe stock decline (-89% 1-year) reflects capital market challenges for pre-revenue biotech amid rising interest rates and risk-off sentiment.
BriaCell operates a classic clinical-stage biotech model: raise capital through equity offerings and grants, fund clinical trials to generate safety/efficacy data, then monetize through partnership deals with large pharma (upfront payments, milestones, royalties) or independent commercialization post-FDA approval. The company's Bria-IMT™ platform targets HER2-positive and triple-negative breast cancer, a market estimated at $8-10B annually. Value creation depends entirely on successful Phase II/III trial readouts demonstrating statistically significant progression-free survival or overall survival benefits. Current cash position (Current Ratio 2.44) suggests 12-18 months runway at typical $15-20M annual burn rate, requiring additional financing before pivotal trial completion.
Clinical trial data releases - interim analysis results for Bria-IMT™ Phase I/II studies showing objective response rates, progression-free survival, or safety signals
FDA regulatory milestones - IND approvals for new indications, Fast Track/Breakthrough Therapy designations, or Phase III trial design agreements
Partnership announcements - licensing deals with major oncology players (Roche, Merck, BMS) providing validation and non-dilutive capital
Equity financing events - dilutive offerings, warrant exercises, or ATM programs that impact share count and cash runway visibility
Competitive landscape shifts - rival checkpoint inhibitor combinations or cancer vaccine data from competitors affecting perceived differentiation
Clinical trial failure risk - Phase II/III trials have 30-40% success rates in oncology; negative data would likely reduce equity value 70-90% given single-asset focus
Regulatory pathway uncertainty - FDA approval standards for cancer vaccines remain evolving; requirement for overall survival endpoints versus surrogate markers could extend timelines 3-5 years and increase costs $100M+
Reimbursement landscape - payer willingness to cover novel immunotherapy combinations at premium pricing ($150K+ annual treatment costs) affects commercial viability even post-approval
Checkpoint inhibitor market saturation - Keytruda, Opdivo, Tecentriq dominate with established efficacy; Bria-IMT™ must demonstrate clear differentiation in head-to-head or combination studies
CAR-T and ADC competition - alternative modalities (cell therapies, antibody-drug conjugates) showing strong efficacy in breast cancer may capture market share before vaccine approval
Big pharma pipeline encroachment - Roche, Pfizer, Gilead advancing HER2-targeted therapies with superior resources and faster development timelines
Dilution risk - micro-cap market cap with negative $20M+ annual cash flow requires frequent equity raises; share count likely to increase 50-100% before commercialization
Going concern risk - if clinical data disappoints or capital markets remain closed, company may lack resources to complete pivotal trials, forcing asset sales at distressed valuations or bankruptcy
Warrant overhang - previous financings likely included warrants that create selling pressure when exercised, particularly if stock rallies on positive news
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, capital availability for biotech financing is highly cyclical, with risk-on environments enabling easier fundraising at better valuations. Economic downturns compress biotech valuations and reduce partnership appetite from large pharma managing their own budgets.
High negative sensitivity. Pre-revenue biotechs are valued on discounted future cash flows 5-10 years out, making them extremely sensitive to discount rate changes. Rising rates from 0.25% (2021) to current 4.5-5% range have compressed biotech multiples 60-80%. Additionally, higher rates increase opportunity cost of holding cash-burning equities versus risk-free Treasuries, reducing speculative capital flows into clinical-stage names. Financing costs for any debt instruments also rise, though BCTX currently has zero debt.
Minimal direct exposure - company has no debt (Debt/Equity 0.00) and doesn't rely on credit markets for operations. Indirect exposure exists through biotech sector credit conditions affecting partnership economics and acquisition premiums from strategic buyers who use leveraged financing.
growth/speculative - Appeals to high-risk tolerance investors seeking asymmetric returns from binary clinical catalysts. Typical holders include biotech-focused hedge funds, retail momentum traders, and venture-style public equity investors. Not suitable for value or income investors given negative earnings, no dividends, and high probability of total loss. Recent -89% decline has likely concentrated ownership among distressed/contrarian players betting on clinical surprise or takeout.
high - Micro-cap biotech with single-asset focus exhibits extreme volatility. Stock likely moves 20-50% on clinical updates, 30-70% on partnership news. Implied volatility typically 80-120% reflecting binary outcome distribution. Beta to broader market likely 1.5-2.0x, but idiosyncratic risk dominates systematic risk.